Potential clinical utility of copeptin (C-terminal provasopressin) measurements in clinical medicine.
AffiliationDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland
MetadataShow full item record
AbstractCopeptin is a 39-amino-acids containing glycosylated peptide derived from the C-terminal part of the arginine vasopressin (AVP) precursor. In the process of proteolysis the AVP precursor is processed to AVP, neurophysin II, and copeptin in equimolar amounts. In contrast to AVP, copeptin remains stable for several days at room temperature in serum or plasma. Hence, copeptin serves as a bona fide biomarker of AVP release. We briefly summarise clinical utility of copeptin in the diagnosis of diabetes insipidus. We also discuss potential applications of copeptin measurements in hyponatraemic states, assessment of an anterior pituitary function, as well as a wide range of several acute and chronic medical conditions, such as myocardial infarction, stroke or diabetes mellitus.
CitationPotential clinical utility of copeptin (C-terminal provasopressin) measurements in clinical medicine. 2016, 124 (3):173-7 Exp. Clin. Endocrinol. Diabetes
JournalExperimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association